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Abstract 
Purpose: To investigate the expression matrix metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs) in ulcerative colitis (UC) patients admitted to The First Affiliated Hospital of 
Nanchang University, Nanchang, Jiangxi, China. 
Methods: The expression of MMPs and TIMPs)  was evaluated in 50 patients (36 males, 14 females) 
with UC who were admitted to The First Affiliated Hospital of Nanchang University, Nanchang, 330006, 
Jiangxi, China. Tissue samples obtained from core needle biopsies were evaluated using 
immunochemistry techniques. 
Results: MMP-9 and TIMP-1 were strongly expressed in the glandular epithelium and inflammatory 
cells. In addition, the expression was coupled with changes in the tissue architecture and inflammation 
in the lamina propria. The expression of MMPs and weak activation of their inhibitors was related to UC 
progression. There were significant correlations between MMP expression and histopathological 
parameters (p = 0.051, R = 0.392). MMP expression correlated with weaker expression of TIMPs (p = 
0.032, R = 0.0581) 
Conclusion: MMP-2, MMP-7, and MMP-9 are potential targets for therapeutic control of UC. 
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Ulcerative colitis (UC) is a chronic inflammatory 
bowel disease that usually causes inflammation 
in the large intestine [1]. As an autoimmune 
disease, UC is influenced by environmental and 
genetic factors [2] and causes ulcers and 
inflammation in the colon [3]. The incidence of 
UC has increased gradually in recent years [4]; 
symptoms include bloody diarrhoea, fever, 
abdominal pain, and weight loss [5]. The 
pathogenesis of the disease is not fully 
understood, but a genetic risk is presumed [6]. 
The treatment of UC includes anti-inflammatory 
drugs and therapy targeted to the immune 
response [7,8]. 
 
Matrix metalloproteinases (MMPs) are 
proteolytic calcium-dependent enzymes 
that contain zinc and belong to the 
metzincin superfamily [9,10]. These 
enzymes play an important role in the 
degradation of extracellular matrix 
protein by cleaving its components [11]. 
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MMPs are also involved in cell 
proliferation, adhesion, differentiation, 
and dispersion, and programed cell 
death [12]. Excreted by endothelial cells, 
neutrophils, macrophages, neutrophils, 
and lymphocytes [13,14], MMPs are 
controlled by tissue inhibitors of 
metalloproteinases (TIMPs) [15]. The 
balance between MMPs and TIMPs 
must be controlled to maintain and 
remodel cells and tissues. Imbalances in 
these proteins can lead to diseases such 
as tissue fibrosis, cardiovascular 
diseases, ulcers, and inflammation [15]. 
 
In this study, we evaluated the 
immunohistochemical associations of 
MMPs and TIMPS, specifically MMP-2, 
MMP-7, and MMP-9 and TIMP-1 and 
TIMP-2, respectively, in 50 patients with 
UC and their correlations with 
histochemical and pathological 
parameters. Increased understanding of 
the expression of these proteins in UC 




The study complied with National Institutes of 
Health guidelines [16] and was approved by 
Bioethics Committee of The First Affiliated 
Hospital of Nanchang University, Nanchang, 
Jiangxi, China (ref no. NU/FAH/BioEt/2014-16A).   
 
The study enrolled 50 patients (36 males, 14 
females) diagnosed with UC. All of the patients 
were older than 21 years of age. Core needle 
biopsy samples embedded in paraffin were 
obtained from the Department of 
Gastroenterology and Surgery, Chinese Central 
Hospital. 
 
All of the reagents were purchased from 
Novocastra Reagents (Leica 
Microsystems, Germany), including 
rabbit anti-Smad4, rabbit anti-Smad6, 
and rabbit anti-Smad7 monoclonal 
antibody for the MMPs and mouse 
monoclonal antibody for TIMP-1 and -2. 
All of the sections examined were 
counterstained with haematoxylin and 
eosin (H&E) before histopathological 
evaluation. 
 
The formalin-fixed tissue specimens 
embedded in paraffin were cut into 4-
μm-thick sections using a HM 450 sliding 
microtome (Thermo Fisher Scientific, 
USA). The sections were deparaffinised 
in xylene and rehydrated with alcohol. 
The sections examined for MMP-2 and 
TIMP-1 were placed in a microwave 
oven for 30 min, treated with citrate 
buffer, and then subjected to antigen 
retrieval using a pressure chamber. 
Slides were incubated with the primary 
antibodies for MMP-2, MMP-7, MMP-9, 
TIMP-1, and TIMP-2, diluted 1:70, and 
kept overnight at 4 °C. Then, they were 
incubated for 20 – 30 min in amplifying 
reagent at room temperature. The 
resulting antigen-antibody complex 
activity was detected and visualised 
using diaminobenzidine (DAB), and the 





Statistical analysis was carried out using SPSS 
16.0 (SPSS, USA). Student’s ݐ-test was used to 
compare the different groups and the correlations 
between parameters were calculated using 
Spearman’s rank correlation. P < 0.05 was 




Of the 50 patients with UC studied, acute, 
moderate, indefinite, and no epithelial dysplasia 
was found in 4, 14, 20, and 12 patients, 
respectively (Table 1). Evaluating the UC 
disease activity using the protocol developed by 
Geboes et al [17], 30 subjects had chronic UC, 8 
were active cases, and 12 subjects had inactive 
UC (Table 1). 
 
Table 1: Gender, grade of dysplasia and disease activity in the investigation 
 
Sex (N) Grade of dysplasia (N) Disease activity (N) 
Female Male Nil Indefinite Moderate Acute Inactive Active Chronic 
14 36 12 20 14 4 12 8 30 
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Note: N denotes number 
 




Ulcerative colitis (UC) 











Weak Average Strong 
MMP-2 2 (4%) 36 (72%) 8 (16%) 4 (8%) 8 (16%) 36(72%) 5(10%) 1(2%) 
MMP-7 29 (58%) 11(22%) 9 (9) 1(2%) 3(6%) 18(36%) 16(32%) 13(26%) 
MMP-9 4 (8%) 16 (32%) 11 (22%) 19 (38%) 2(4%) 16(32%) 13(26%) 19(38%) 
 
Examining glandular cells, the MMP-2 
expression was weak in the glandular 
epithelium of 50 cases, covering 73.3 % 
of the patients with UC and in 
inflammatory cells in 72 % of the cases. 
MMP-2 expression in the glandular tubes 
was average and strong in 16 and 8 % of 
the cases, respectively, compared with 
10 and 2 % of the inflammatory cells 
(Table 2). 
 
In comparison, no MMP-7 expression 
was seen in the glandular epithelium of 
29 patients (58 %), compared with 6 % 
of the inflammatory cells. There was 
weak expression in the glandular cells of 
22 % of the cases, compared with 36 % 
of the inflammatory cells. MMP-9 
expression was weak in both the 
glandular and inflammatory cells in 16 % 
of the cases; average expression of both 
was observed in 32 % of the cases 
(Figure 1 and Table 2). 
 
Strong TIMP-1 expression was found in 
the glandular epithelium in 32 cases (64 
%) and in 40 % of the inflammatory 
infiltrate cells. There was weak TIMP-2 
in glandular epithelium in 44 % of the 
cases, compared with 33 % of the 
inflammatory cells (Figure 2a, b). 
 
There was a strong correlation between 
the expression of MMPs in the glandular 
epithelium and the presence of ulcers 
(p = 0.051, R = 0.392). In addition, MMP-
2 in the glandular epithelium tended to 
be correlated with a change in the tissue 
architecture (p = 0.076, R = 0.381) and 
the presence of neutrophils in the lamina 
propria (p = 0.077, R = 0.371) (Fig. 1a). 
 
The expression of MMP-7 in the 
glandular epithelium was correlated with 
erosions (p = 0.031, R = 0.492). 
Decreased MMP-9 expression was 
observed with altered tissue architecture 
(p = 0.067, R = −0.392) (Fig. 1b, c). 
 
Figure 1: Immunohistochemical expression of (a) MMP-2, (b) MMP-7 and (c) MMP-9 in glandular 
epithelium and inflammatory cells 
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Figure 2: Immunohistochemical expression of (a) TIMP-1 and (b) TIMP-2 in glandular epithelium and 
inflammatory cells 
The expression of MMP-2 in the lamina 
propria was correlated with the presence 
of neutrophils in an inflammatory 
infiltrate. In addition, the expression 
TIMP-1 correlated with eosinophils in the 
lamina propria (p = 0.024, R = 0.612) 
and neutrophils in the glandular 
epithelium (p = 0.032, R = 0.0581). 
There was a significant correlation with 
the expression of TIMP-2 in the 
glandular epithelium, but not with 




The expression of various metalloproteinases 
and their inhibitors observed in the patients with 
UC was related to the stage of the disease. 
There was weak MMP-7 expression in the 
glandular epithelium in 60 % of the cases with an 
inflammatory infiltrate. Weak MMP-2 expression 
was observed in the inflammatory infiltrate 
contrasting strong expression in the glandular 
epithelium, as noted by von Lampe et al [18]. 
MMP-2 expression was associated with erosions 
in the glandular epithelium. The expression of 
MMP-2 was also mainly associated with 
mesenchymal cells and neutrophils in the 
glandular epithelium and an inflammatory 
infiltrate. MMP-9 expression was observed in 
both the glandular epithelium and inflammatory 
infiltrate, as reported in patients with UC [19]. In 
addition, the protein activity in UC increased with 
the homogeneity of the inflamed mucosa. 
 
The tissue architecture of the colon 
changed with the level of MMP-9 
expression, implying that MMP-9 
expression plays a role in the chronic 
inflammation of the tissue lining of the 
colon and remodelling of the tissue 
architecture.  Our results revealed that 
MMP-9 plays a crucial role in the 
pathogenesis of UC, as reported 
elsewhere [20,21], suggesting MMP-9 as 
a potential target for treatment. TIMP-1 
and TIMP-2 also play vital roles in 
regulating the activity of MMPs and 
maintaining equilibrium. The expression 
of TIMP-1 in an inflamed ulcer in UC has 
been reported [22]. 
 
Limitation of the study 
 
One limitation of this study is that the tissue 
samples were from a Chinese population; the 
correlation between the expression of MMPs and 





The expression of MMPs and their inhibitors 
reflects UC progression. There are significant 
correlations between MMPs and histopatho-
logical parameters. MMP-2, MMP-7 and MMP-9 
are potential targets for reducing the progression 
of UC in patients by using inhibitors such as 
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